Market Executive Summary

The global Cardiac Biomarkers market was valued at US$ 704.2 million in 2023 and is anticipated to reach US$ 1315.7 million by 2030, witnessing a CAGR of 9.2% during the forecast period 2024-2030.

Cardiovascular diseases are leading cause of morbidity and mortality globally. Biomarkers are generally used as an indicator forparticular diseases such as rheumatic and congenital heart diseases and cardiac arrhythmia. Cardiac biomarkers are measurable and quantifiable biological parameters. These are specifically used to check the presence or severity of cardiovascular diseases. Cardiac biomarkers are the substances that are released into blood when heart is damaged. These biomarkers are also used for diagnosing and monitoring diseases such as coronary syndrome or cardiac ischemia.

The symptoms of these diseases includes chest pain, shortness of breath and nausea that ultimately leads to heart attack or angina. Cardiac biomarker tests helps to detect presence of coronary syndrome and cardiac ischemia to evaluate its severity and diagnosis.

The prevention of cardiac diseases by monitoring the heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment.

Cardiac biomarkers are protein-based traceable substances used as an indicator of biologic state and used for diagnostic and prognostic purposes associated with heart. Cardiac biomarkers are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infraction, congestive heart failure, acute coronary syndrome (ACS) among others.

The cardiac biomarkers that are widely used as an integrated diagnostic approach for CVDs include CK-MB, troponin I and T, myoglobin, BNPs, IMA and few others. Cardiac biomarkers market has witnessed a greater demand over the past five to six years. 

This report aims to provide a comprehensive presentation of the global market for Cardiac Biomarkers, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cardiac Biomarkers.

Report Scope

The Cardiac Biomarkers market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Cardiac Biomarkers market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. 

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Cardiac Biomarkers companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Global Cardiac Biomarkers Companies Covered

Abbott, Abbott, F. Hoffmann-La Roche, Advanced ImmunoChemical, AgPlus Diagnostics, BG Medicine, BioLegend, bioMérieux, Bio-Rad Laboratories, BODITECH MED

Global Cardiac Biomarkers Market, Segment by Type

Troponin

CK-MB

Natriuretic Peptides - BNP and NT-proBNP

Myoglobin

Others

Global Cardiac Biomarkers Market, Segment by Application

Acute Coronary Syndrome

Myocardial Infarction

Congestive Heart Failure

Others

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Cardiac Biomarkers companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 12: The main points and conclusions of the report.